Life Extension Magazine November 2005
A New Weapon to Fight Prostate Cancer
By Dale Kiefer
By Dale Kiefer
Scientists recently uncovered a novel component of milk thistle that may be a powerful new weapon for preventing and possibly even treating prostate cancer.
This phytochemical, called isosilybin B, potently suppresses the growth and runaway proliferation of human prostate cancer cells. Isosilybin B also suppresses the activity of a genetic factor that is expressed in most human cancers. Moreover, this potent phytonutrient inhibits the secretion of a protein that may contribute to prostate cancer progression and metastasis.
Importantly, isosilybin B is active against both hormone-dependent and hormone-independent prostate cancers. Isosilybin B may thus offer the most powerful protection against prostate malignancies of any phytonutrient yet discovered.
The beneficial effects of silymarin and silibinin extracts from the milk thistle plant have long been known. Scientists recently identified a new milk thistle extract called isosilybin B that shows remarkable effects in fighting prostate cancer via several mechanisms.
At the Research Triangle in North Carolina, scientists investigated the anti-cancer activities of milk thistle extracts and of purified milk thistle constituents against three different human prostate carcinoma cell lines: LNCaP, DU145, and PC3. These are the most commonly used laboratory models of human prostate cancer.1
Examining several end points related to anti-proliferative activity against prostate cancer, the scientists found isosilybin B to be the most potent prostate cancer fighter in nearly all of the parameters studied.
First, the researchers tested individual milk thistle constituents against DU145 cells, a line of hormone-independent human prostate cancer cells. The cancer cells were exposed to varying concentrations of milk thistle compounds for three days. Isosilybin B produced significant growth inhibition of nearly 69% and was the most efficacious of all milk thistle compounds tested. By contrast, the second most effective agent inhibited cancer cell growth by only 38%, while most of the phytochemicals tested showed no activity at all.1
Next, the investigators examined the effects of milk thistle components against hormone-dependent LNCaP prostate cancer cells and hormone-independent PC3 cells. Isosilybin B was the most effective growth suppressor of LNCaP cells, and was also effective against the PC3 cancer cells. The researchers noted, “isosilybin B was the most potent growth inhibitory constituent of silymarin-based milk thistle extracts and was often more effective than silibinin or silymarin extracts.”1
In another experiment, the scientists examined how milk thistle constituents affect the secretion of prostate-specific antigen (PSA) by LNCaP cells. A protein synthesized in the prostate gland, PSA serves as a marker for prostate enlargement and cancer. Isosilybin B and its mirror-image isomer, isosilybin A, reduced PSA secretion, while other milk thistle constituents did not show this activity.1 The effect of isosilybins A and B on PSA is particularly noteworthy, as emerging evidence suggests PSA itself may play a role in prostate cancer’s progression and metastasis.2-4 (See “Does PSA Promote Prostate Cancer?” Life Extension, June 2005.) Isosilybins may thus offer a novel way to modulate PSA levels.
Continuing their investigation, the Research Triangle scientist found for the first time that milk thistle extracts suppress the activity of the DNA topoisomerase IIalpha promoter, a genetic factor that is indispensable for cellular proliferation. A recent meta-analysis found that topoisomerase IIalpha is one of the most commonly activated genes across a large majority of human cancers.1 In DU145 prostate cancer cells, isosilybin B was the milk thistle constituent that most potently and effectively suppressed this gene promoter.1
New Findings, New Priorities
These recent research findings concerning isosilybin B have significant implications for individuals and scientists interested in prostate cancer prevention and treatment.
Until recently, scientists had focused their research efforts on milk thistle components such as silymarin and silibinin, which in turn have become widely available in herbal supplements. However, as the Research Triangle team noted, “isosilybin B composes no more than 5% of silymarin, and is absent from silibinin.”1 In other words, preparations currently sold as milk thistle extract, silymarin, or silibinin may contain little or no isosilybin B.
While the scientists reported some anti-cancer activity among other milk thistle constituents, it was necessary to apply those compounds at much higher concentrations to achieve the anti-cancer effect elicited by a relatively small dose of isosilybin B.1 The bottom line? Isosilybin B appears to be more potent than other milk thistle isomers against prostate cancer. According to the Carolina scientists, “identification of isosilybin B as the most potent prostate carcinoma inhibitor indicates that any subsequent preclinical or phase I trials should include extracts enriched for this component.”1
Other Milk Thistle Components
The crude extraction of milk thistle fruits or seeds yields a polyphenolic flavonoid called silymarin. Silymarin is actually a mixture of phytochemicals, the most prominent of which are silibinin (also spelled as silybin), isosilybin, silychristin, and siliydianin.5
Most research has focused on the beneficial effects of silymarin and silibinin. Studies suggest that silymarin helps prevent the growth of human cancer cells in vitro6,7 and protects laboratory animals against the growth of certain tumors.6-8
Silibinin has shown potent antioxidant and anticarcinogenic effects,6 and may work synergistically with chemotherapy drugs used to treat prostate cancer.9 Many currently available milk thistle products contain primarily silymarin, and some are standardized in silibinin content, perhaps in light of the National Cancer Institute’s assertion that silibinin is the most active constituent of milk thistle.10
In 2003, Harvard Medical School researchers learned that the milk thistle compound isosilybin is not one, but is actually two distinct chemicals, isosilybin A and isosilybin B. Likewise, they found that silibinin comprises two chemicals, silybin A and silybin B. These closely related but distinct isomers belong to a class of plant chemicals called flavonolignans.11
Effects of Silymarin and Silibinin
Isosilybin is now poised to join the ranks of the cancer-fighting milk thistle components silymarin and silibinin, two extracts whose effects already are supported by a large body of research. Indeed, numerous studies of silymarin and silibinin paved the way for further studies on milk thistle constituents.
Silymarin and silibinin appear to offer protection against prostate and other cancers. Studies have shown that both silymarin and silibinin are strong antioxidants and inhibit human carcinoma cell growth and DNA synthesis.6 Both compounds may help protect against skin cancer and breast cancer.7,8,12,13
Silymarin and silibinin also show promise in preventing prostate cancer. Research conducted in 2004 indicates that one or more silymarin constituents inhibit mitogenic and survival signaling by prostate cancer cells. This signaling is crucial to cancer cells’ ability to survive and thrive. “In general, advanced stage cancer cells harbor many constitutively active mitogenic signaling and anti-apoptotic mechanisms, which make them less dependent on external growth factors as well as resistant to chemotherapeutic agents,” noted University of Colorado researchers. They add, however, that silymarin’s ability to tackle cancer from a number of angles holds great promise: “In this regard, silibinin . . . has shown [multi-tasking] anti-cancer effects in different cancer cells.”14
Another research team investigated the efficacy of silibinin against prostate cancer. Based on the “strong antioxidant and anticarcinogenic effects of silibinin, the fact that silibinin is used clinically and marketed as a dietary supplement, and [considering] the bioavailability of silibinin in prostate after its oral administration . . . we reasoned that silibinin also could be a useful agent for the intervention of human [prostate cancer],” wrote the researchers. After conducting a variety of complex cell culture assays, they determined that “silibinin has strong potential to be developed as an antiproliferative differentiating agent for the intervention of hormone-refractory human prostate cancer.”6
In another 2004 report, the University of Colorado research team noted that silymarin and silibinin inhibit the secretion of pro-angiogenic factors from tumor cells, which are necessary for tumor cells to recruit the blood supply required for their continued growth. Furthermore, silymarin and silibinin inhibit the growth of cancer cells in culture, while inducing programmed cell death, or apoptosis. Silibinin may also work synergistically with the chemotherapy drug doxorubicin to help kill cancer cells, making it a strong candidate for combination therapy.9
Silibinin has even exerted cancer-fighting effects against an advanced form of prostate cancer. Adding silibinin to the diet of mice that had received a surgical graft of advanced human prostate tumor cells resulted in decreased proliferation and increased programmed cell death of the cancer cells.15
Animal and human studies alike have shown milk thistle to be non-toxic. “At high doses . . . a laxative effect is possible due to increased bile secretion and flow,” noted a report published in Alternative Medicine Review. “Mild allergic reactions have also been noted but were not serious.”16 However, as one researcher noted regarding milk thistle’s use as a pharmaceutical in Belgium, “The drug has a general safety pattern comparable to placebo.”17
Combining the wisdom of the ancients with cutting-edge medical technology, science is discovering exciting new applications for milk thistle in the fight against prostate cancer. Isosilybin B, a previously little-known constituent of milk thistle extract, appears to hold great potential for preventing this much-dreaded malady.